Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
A few young children may be cured and others given a better shot
at long-term survival thanks to a new intense, multi-pronged
therapy regimen administered to young patients with a rare,
aggressive type of brain tumor, say Dana-Farber Cancer Institute
researchers who directed the first study of its kind.
Previously, children with the extremely rare brain cancer called
atypical teratoid/rhabdoid tumor (AT/RT) typically lived less than
a year. Results of a multi-center trial recently published in the
Journal of Clinical Oncology showed that more than 70 percent of 20
such patients – four of them treated at Dana-Farber – have survived
more than two to three years with the new treatment regimen. Most
relapses occurred within months, and so "once the children are past
the two-year mark, we're pretty hopeful they are cured," says Susan Chi, MD, who led the Dana-Farber study along with Mark Kieran, MD, PhD,
and Mary Ann Zimmerman, CPNP.
Key to the improved outcomes was "a lot of treatment over a
short period of time, early on," says Chi. The regimen included a
combination of surgery, high-dose radiation, and chemotherapy. A
portion of the latter was delivered directly to the brain and
The researchers say the study is the first to prospectively
evaluate the new treatment regimen, which they developed and first
administered in a small pilot study with encouraging results.
The study authors note that the regimen succeeded in extending
"progression-free survival" - the period before the cancer began
growing again - to a median of 27 months. With previous treatments,
that period averaged six to 11 months, Chi says.
Some children who underwent the powerful treatments had
complications such as infections and long hospitalizations for
cycles of chemotherapy, says Chi. In addition, the high doses of
radiation may have long-term cognitive effects, and those patients
will be carefully monitored.
Despite these issues, Chi says, parents of the surviving
patients are "very, very happy" with the outcomes. Other families
have brought children with AT/RT to Dana-Farber because of the
successes, and five of them are currently undergoing treatment.
"We're really pleased," Chi says. "We're not curing everybody
yet, but it's a great place to start."
– Richard SaltusRichard_Saltus@dfci.harvard.edu
Search by last name:
Browse directory of